Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

Presentation TCT 2016

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Presenter: Sanjay Kaul, Jeffrey J. Popma, John D. Puskas

November 01, 2016

Presentation TCT 2016

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Michael Haude

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Salvatore Cassese

November 01, 2016

Presentation TCT 2016

Subgroup Analyses: How Useful or Harmful Are They?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Sanjay Kaul

November 01, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Presentation TCT 2015

I Believe That Most PCI Procedures for Stable CAD Are NOT Worth the Time/Effort/Risk/Money!

Presenter: Eric R. Bates, Spencer B. King III, Sanjay Kaul

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2015

Keynote Lecture 3: Single-Center vs Multicenter Trials Pros, Cons, and Integration Into Evidence

Presenter: Ajay J. Kirtane, Roxana Mehran, Sanjay Kaul

October 12, 2015

Presentation TCT 2015

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

Presenter: Robert A. Harrington, Pascal Vranckx, Sanjay Kaul

October 11, 2015

Presentation TCT 2015

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Presenter: Stuart J. Pocock, Jan Tijssen, Sanjay Kaul

October 11, 2015

Advertisement

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Subgroup Analyses: How Useful or Harmful Are They?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Limitations of Pharmacotherapy Clinical Trial Design

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

I Believe That Most PCI Procedures for Stable CAD Are NOT Worth the Time/Effort/Risk/Money!

Discussion Highlights Merits, Limitations of Small Trials

Keynote Lecture 3: Single-Center vs Multicenter Trials Pros, Cons, and Integration Into Evidence

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content